-
Mashup Score: 2Community Focus Archives | VJHemOnc - 22 day(s) ago
Intended for community physicians, this channel aims to inform clinical practice through expert interviews from major international congresses. The diagnosis, treatment and management of patients with hematological conditions and malignancies is rapidly evolving, and with an influx of therapeutic options, physicians may find it difficult to decide which management strategy is best for their patients. Although cutting-edge research is at the heart of clinical development, data from trials are not always
Source: www.vjhemonc.comCategories: General Medicine NewsTweet
-
Mashup Score: 2
As SOHO continues to connect with a growing global community, we remain focused on supporting hematologic oncologists
Source: sohoinsider.comCategories: General Medicine News, Partners & KOLsTweet-
Learn about how SOHO is growing globally and supporting future leaders in #hemonc. https://t.co/EuA0gSrbAs
-
-
Mashup Score: 0Meetings / Conferences Archives - SOHO Insider - 1 month(s) ago
Meeting and conference coverage in blood cancers from around the global, including ASCO, ASH, SOHO, ESMO, SITC, EHA, the Tandem Meetings, and others.
Source: sohoinsider.comCategories: General Medicine News, Partners & KOLsTweet-
Are you looking for the latest #HemOnc updates? Check out our conference news page on sohoinsider at https://t.co/lewuGEDbFn https://t.co/Ntj4OUd3W2
-
-
Mashup Score: 2Community Focus Archives | VJHemOnc - 1 month(s) ago
Intended for community physicians, this channel aims to inform clinical practice through expert interviews from major international congresses. The diagnosis, treatment and management of patients with hematological conditions and malignancies is rapidly evolving, and with an influx of therapeutic options, physicians may find it difficult to decide which management strategy is best for their patients. Although cutting-edge research is at the heart of clinical development, data from trials are not always
Source: www.vjhemonc.comCategories: General Medicine NewsTweet-
Introducing: the Community Focus channel!👩⚕️👨⚕️ This channel aims to inform clinical practice through expert interviews from international congresses.🎥 🏥 Designed for HCPs to help bridge the gap between research & care. Check it out here: 👉 https://t.co/UMwJjYuHtn #HemOnc https://t.co/PeJH6ro07b
-
-
Mashup Score: 1Krish Patel joins Sarah Cannon as director of lymphoma research - The Cancer Letter - 6 month(s) ago
Krish Patel was appointed director of lymphoma research at Sarah Cannon Research Institute. To access this subscriber-only content please log in or subscribe.If your institution has a site license, log in with IP-login or register for a sponsored account.**Not all site licenses are enrolled in sponsored accounts.Login Subscribe
Source: cancerletter.comCategories: General Medicine News, Oncologists1Tweet-
Krish Patel (@KrishPatelMD) joins Sarah Cannon (@SarahCannonDocs) as director of lymphoma research. #HemOnc https://t.co/IpMQBCvbMf https://t.co/jrjMvJg1Xr
-
-
Mashup Score: 4Maternal and obstetric outcomes in women with pregnancy-associated haematological malignancies: an observational nationwide cohort study - 7 month(s) ago
This nationwide observational study examines pregnancy-associated haematological malignancies in France, revealing no significant difference in overall survival between women diagnosed during pregnancy and post-pregnancy. Our data highlight an increased frequency of severe maternal morbidity and obstetric complications among women diagnosed during pregnancy. Notably, the study underscores the necessity for specialised care to manage these complex cases effectively.
Source: www.thelancet.comCategories: General Medicine News, Oncologists1Tweet-
NEW: Maternal and obstetric outcomes in women with pregnancy-associated haematological malignancies: an observational, nationwide cohort study #hemonc https://t.co/nD7QDhkIfE https://t.co/wun97ymofN
-
-
Mashup Score: 4Sexual health and emotional wellbeing of patients with haematological malignancies: general review - 8 month(s) ago
Sexual health is an important aspect of a person’s life. Many patients and haematologists believe that intimacy and sexuality issues are substantial during cancer treatment. The haematological cancer disease, diagnosis, shock of the announcement, treatment, and follow-up appointments, can all have negative effects on the quality of life of patients, their partners, other family members, and friends. Addressing the intimate aspects of patients’ lives not only enhances their wellbeing but also contributes to the quality of their survivorship.
Source: www.thelancet.comCategories: General Medicine News, Oncologists1Tweet-
Paper 1 explores the factors affecting the sexual life of patients with haematological malignancies, different methods to assess sexual function, as well as management approaches of sexual wellbeing among these patients #hemonc https://t.co/y8jhbd6NDc https://t.co/fMIruG2Go7
-
-
Mashup Score: 6
PURPOSE Human leukocyte antigen (HLA) mismatching can reduce survival of patients with blood cancer after hematopoietic cell transplantation (HCT). How recent advances in HCT practice, in particular graft-versus-host disease (GVHD) prophylaxis by post-transplantation cyclophosphamide (PTCy), influence HLA risk associations is unknown. PATIENTS AND METHODS The study included 17,292 unrelated HCTs with 6-locus high-resolution HLA typing, performed mainly for acute leukemia or related myeloid neoplasms between 2016 and 2020, including 1,523 transplants with PTCy. HLA risk associations were evaluated by multivariable Cox regression models, with overall survival (OS) as primary end point. RESULTS OS was lower in HLA mismatched compared with fully matched transplants (hazard ratio [HR], 1.23 [99% CI, 1.14 to 1.33]; P < .001). This was driven by class I HLA-A, HLA-B, HLA-C (HR, 1.29 [99% CI, 1.19 to 1.41]; P < .001) but not class II HLA-DRB1 and HLA-DQB1 (HR, 1.07 [99% CI, 0.93 to 1.23]; P =
Source: ascopubs.orgCategories: General Medicine News, Oncologists1Tweet-
Human Leukocyte Antigen Mismatching and Survival in Contemporary Hematopoietic Cell Transplantation for Hematologic Malignancies: https://t.co/pkokKpnWeq @IztfE #hemonc
-
-
Mashup Score: 7
PURPOSE Access to allogeneic hematopoietic cell transplantation (HCT) remains limited among persons of non-European ancestry if human leukocyte antigen (HLA) matching is required. We evaluated whether post-transplant cyclophosphamide (PTCy)–based graft-versus-host disease (GVHD) prophylaxis improved HCT outcomes with HLA-matched unrelated donor (MUD) and mismatched unrelated donor (MMUD) HCT when compared with calcineurin inhibitor (CNI)–based prophylaxis. METHODS Three-year overall survival (OS) and GVHD-free, relapse-free survival (GRFS) were compared between adult recipients undergoing initial MUD or single HLA locus MMUD HCT with either PTCy- or CNI-based prophylaxis who were reported to the Center for International Blood and Marrow Transplant Research between 2017 and 2021. RESULTS Included were 10,025 HCT recipients (7,272 recipients of MUD with CNI, 1,681 MUD with PTCy, 613 MMUD with CNI, and 459 MMUD with PTCy) who underwent HCT for acute leukemia (70.9%) or myelodysplastic syn
Source: ascopubs.orgCategories: General Medicine News, Oncologists1Tweet-
Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis Attenuates Disparity in Outcomes Between Use of Matched or Mismatched Unrelated Donors ➡️ https://t.co/z6TgWikO34 @BrianShafferMD @DrStevenDevine #hemonc
-
-
Mashup Score: 33
Alan Skarbnik, MD, and Manni Mohyuddin, MBBS, discuss the concept of MRD in hematologic malignancies.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet-
My latest #HemOnc Pulse is out W @ManniMD1 & @ASkarbnik discussing the "concept of MRD" in Heme malignancies. Impact of MRD likely varies based on the Dx & goals of Tx, but it is critical to address. Listen to the entire discussion here @Blood_Cancers https://t.co/S93jVt0nqp
-
Introducing: the Community Focus channel!👩⚕️👨⚕️ This channel aims to inform clinical practice through expert interviews from international congresses.🎥 🏥 Designed for HCPs to help bridge the gap between research & care. Check it out here: 👉 https://t.co/UMwJjYuHtn #HemOnc https://t.co/PeJH6ro07b